Charles River Laboratories International (CRL) Cash from Financing Activities (2016 - 2025)
Charles River Laboratories International has reported Cash from Financing Activities over the past 17 years, most recently at -$51.9 million for Q4 2025.
- Quarterly results put Cash from Financing Activities at -$51.9 million for Q4 2025, up 31.65% from a year ago — trailing twelve months through Dec 2025 was -$536.7 million (up 2.58% YoY), and the annual figure for FY2025 was -$536.7 million, up 2.58%.
- Cash from Financing Activities for Q4 2025 was -$51.9 million at Charles River Laboratories International, up from -$152.6 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for CRL hit a ceiling of $518.0 million in Q2 2021 and a floor of -$285.9 million in Q2 2024.
- Median Cash from Financing Activities over the past 5 years was -$61.7 million (2023), compared with a mean of -$27.1 million.
- Biggest five-year swings in Cash from Financing Activities: surged 597.57% in 2021 and later tumbled 674.1% in 2025.
- Charles River Laboratories International's Cash from Financing Activities stood at -$219.0 million in 2021, then decreased by 13.69% to -$249.0 million in 2022, then surged by 149.63% to $123.6 million in 2023, then plummeted by 161.41% to -$75.9 million in 2024, then skyrocketed by 31.65% to -$51.9 million in 2025.
- The last three reported values for Cash from Financing Activities were -$51.9 million (Q4 2025), -$152.6 million (Q3 2025), and -$226.9 million (Q2 2025) per Business Quant data.